GenoType MTBDRs/ line probe assay shortens time to diagnosis of extensively drug-resistant tuberculosis in a high-throughput diagnostic laboratory

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 12, 2012, Pages 1298-1305

  Barnard, Marinus ^a,b,c   Warren, Rob ^b,c   Van Pittius, Nico Gey ^b,c   Van Helden, Paul ^b,c   Bosman, Marlein ^a   Streicher, Elizabeth ^b,c   Coetzee, Gerrit ^a   O'Brien, Richard ^d  

^a NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c UNIVERSITY OF STELLENBOSCH   (South Africa)

^d FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

Author keywords

GenoType MTBDRplus; GenoType MTBDRsl; Line probe assay; Mycobacterium tuberculosis; XDR TB

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; DIAGNOSTIC AGENT; EMBB PROTEIN, MYCOBACTERIUM TUBERCULOSIS; GLYCOSYLTRANSFERASE; TUBERCULOSTATIC AGENT;

ACID FAST BACTERIUM; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; DELAYED DIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG RESISTANT TUBERCULOSIS; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HIGH THROUGHPUT DIAGNOSTIC LABORATORY; HUMAN; LABORATORY DIAGNOSIS; LINE PROBE ASSAY; MAJOR CLINICAL STUDY; MOLECULAR PROBE; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS; DRUG EFFECT; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENETIC MARKER; GENETICS; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR DIAGNOSIS; MULTIDRUG RESISTANCE; SOUTH AFRICA; SPUTUM; TIME;

AMIKACIN; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ETHAMBUTOL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENETIC MARKERS; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR DIAGNOSTIC TECHNIQUES; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; PENTOSYLTRANSFERASES; RIFAMPIN; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; SPUTUM; TIME FACTORS;

EID: 84871802624     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201205-0960OC     Document Type: Article

References (42)

1. World Health Organization. Global tuberculosis control 2011. WHO/HTM/TB/2011.16. Geneva, Switzerland: World Health Organization; 2011.
2. World Health Organization. Anti-tuberculosis drug resistance in the world: report No. 4. WHO/HTM/TB/2008.394. Geneva, Switzerland: World Health Organization; 2008.
3. World Health Organization. WHO Global Task Force outlines measures to combat XDR-TB worldwide. Geneva, Switzerland: World Health Organization; 2006. Available from: http://www.who.int/mediacentre/news/notes/2006/np29/en/print. html
4. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep 2006;55:301-305.
5. World Health Organization. Global tuberculosis control 2010. WHO/HTM/TB/2010.7. Geneva, Switzerland: World Health Organization; 2010.
6. Stop TB Department, World Health Organization. Frequently asked questions - XDR-TB. Geneva, Switzerland: World Health Organization; 2012. Available from: http://www.who.int/tb/challenges/xdr/faqs/en/index.html
7. Richter E, Rüsch-Gerdes S, Hillemann D. Drug-susceptibility testing in TB: current status and future prospects. Expert Rev Respir Med 2009;3:497-510.
8. Kim SJ, Espinal MA, Abe C, Bai GH, Boulahbal F, Fattorin L, Gilpin C, Hoffner S, Kam KM, Martin-Casabona N, et al. Is second-line antituberculosis drug susceptibility testing reliable? Int J Tuberc Lung Dis 2004;8:1157-1158. (Pubitemid 39201267)
9. Mlambo CK, Warren RM, Poswa X, Victor TC, Duse AG, Marais E. Genotypic diversity of extensively drug-resistant tuberculosis (XDRTB) in South Africa. Int J Tuberc Lung Dis 2008;12:99-104.
10. Tortoli E, Benedetti M, Fontanelli A, Simonetti MT. Evaluation of automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to four major antituberculous drugs: comparison with the radiometric BACTEC 460TB method and the agar plate method of proportion. J Clin Microbiol 2002;40:607-610. (Pubitemid 34130888)
11. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575-1580. (Pubitemid 44780738)
12. World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multi-drug resistant tuberculosis (MDR-TB). Geneva, Switzerland: World Health Organization; 2008. Available from: http://www.who.int/tb/features-archive/policy-statement.pdf
13. Hillemann D, Rüsch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009;47:1767-1772.
14. Kiet VS, Lan NT, An DD, Dung NH, Hoa DV, van Vinh CN, Chinh NT, Farrar J, Caws M. Evaluation of the MTBDRsl test for detection of second-line-drug resistance in Mycobacterium tuberculosis. J Clin Microbiol 2010;48:2934-2939.
15. Said HM, Kock MM, Ismail NA, Baba K, Omar SV, Osman AG, Hoosen AA, Ehlers MM. Evaluation of the GenoType® MTBDRsl assay for susceptibility testing of second-line anti-tuberculosis drugs. Int J Tuberc Lung Dis 2012;16:104-109.
16. Ignatyeva O, Kontsevaya I, Kovalyov A, Balabanova Y, Nikolayevskyy V, Toit K, Dragan A, Maxim D, Mironova S, Kummik T, et al. Detection of resistance to second-line antituberculosis drugs using the GenoType® MTBDRsl assay: a multi-center evaluation and feasibility study. J Clin Microbiol 2012;50:1593-1597.
17. Miotto PA, Cabibbe AM, Mantegani P, Borroni E, Fattorini L, Tortoli E, Migliori GB, Cirillo EM. GenoType MTBDRsl performance on clinical samples with diverse genetic background. Eur Respir J 2012;40:690-698.
18. Lacoma A, Garcia-Sierra N, Prat C, Maldonado J, Ruiz-Manzano J, Haba L, Gavin P, Samper S, Ausina V, Dominguez J. GenoType MTBDRsl for molecular detection of second-line-drug and ethambutol resistance in Mycobacterium tuberculosis strains and clinical samples. J Clin Microbiol 2012;50:30-36.
19. Huang WL, Chi TL, Wu MH, Jou R. Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2011;49:2502-2508.
20. Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W. Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2010;48:1683-1689.
21. Kent PT, Kubica GP. Public health mycobacteriology: a guide for the level III laboratory. U.S. Department of Health and Human Services, Publication No. 86-216546. Atlanta, GA: Centers for Disease Control, 1985.
22. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008;177:787-792. (Pubitemid 351490566)
23. International Organization for Standardization. Medical laboratories: particular requirements for quality and competence. ISO 15189:2007. Geneva, Switzerland: International Organization for Standardization; 2007.
24. Heifets L, Desmond E Clinical mycobacteriology (tuberculosis) laboratory services and methods. In Cole ST, Eisenbach KD, Murray DN Jacobs WJ, editors. Tuberculosis and the tubercle bacillus. Washington, DC: American Society for Microbiology; 2005. pp. 49-70.
25. Johnson R, Jordaan AM, Pretorius L, Engelke E, van der Spuy G, Kewley C, Bosman M, van Helden PD, Warren R, Victor TC. Ethambutol resistance testing by mutation detection. Int J Tuberc Lung Dis 2006;10:68-73. (Pubitemid 43266280)
26. Siddiqi SH. MGIT procedure manual prepared for the FIND MGIT demonstration project. Sparks, MD: BD Diagnostic Systems; 2005.
27. Centers for Disease Control and Prevention. Introducing...Epi Info 7. Atlanta, GA: Centers for Disease Control and Prevention; 2011. Available from: http://www.cdc.gov/epiinfo.
28. Streicher EM, Bergval I, Dheda K, Bottger EC, Gey van Pittius NC, Bosman M, Coetzee G, Anthony RM, van Helden PD, Victor TC, et al. Mycobacterium tuberculosis population structure determines the outcome of genetics-based second-line drug resistance testing. Antimicrob Agents Chemother 2012;56:2420-2427.
29. Laszlo A, Rahman M, Espinal M, Raviglione M. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994-1998. Int J Tuberc Lung Dis 2002;6:748-756. (Pubitemid 34988044)
30. Drobniewski FA, Nikolayevskyy V, Hoffner S, Pogoryelova O, Manissero D, Ozin AJ. The added value of a European Union tuberculosis reference laboratory network - analysis of the national reference laboratory activities. Euro Surveill 2008;13:8076.
31. Maus CE, Plikaytis BB, Shinnick TM. Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005;49:3192-3197. (Pubitemid 41060560)
32. Georghiou SB, Magana M, Garfein RS, Catanzaro DG, Catanzaro A, Rodwell TC. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS One 2012;7:e33275.
33. Barnard M, Coetzee G, Bhyat Z, Bosman M, Koornhof H. Assesment of the GenoType® MTBDRsl line probe assay for the rapid diagnosis of XDR-TB in South Africa [abstract]. Int J Tuberc Lung Dis 2010;14:S301.
34. Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE. Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011;55:2032-2041.
35. Mokrousov I, Otten T, Manicheva O, Potapova Y, Vishnevsky B, Narvskaya O, Rastogi N. Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia. Antimicrob Agents Chemother 2008;52:2937-2939.
36. Van Deun A, Barrera L, Bastian I, Fattorini L, Hoffmann H, Kam KM, Rigouts L, Rüsch-Gerdes S, Wright A. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J Clin Microbiol 2009;47:3501-3506.
37. Zhang X, Zhao B, Liu L, Zhu Y, Zhao Y, Jin Q. Subpopulation analysis of heteroresistance to fluoroquinolone in Mycobacterium tuberculosis isolates from Beijing, China. J Clin Microbiol 2012;50:1471-1474.
38. Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, Weissman D, Marra C, Lalloo UG, Friedland GH. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 2010;181:80-86.
39. Gandhi NR, Andrews JR, Brust JC, Montreuil R, Weissman D, Heo M, Moll AP, Friedland GH, Shah NS. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. Int J Tuberc Lung Dis 2012;16:90-97.
40. Hoek KG, Van RA, van Helden PD, Warren RM, Victor TC. Detecting drug-resistant tuberculosis: the importance of rapid testing. Mol Diagn Ther 2011;15:189-194.
41. Mukinda FK, Theron D, van der Spuy GD, Jacobson KR, Roscher M, Streicher EM, Musekiwa A, Coetzee GC, Victor TC, Marais BJ, et al. Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa. Int J Tuberc Lung Dis 2012;16:196-202.
42. Parsons LM, Somoskovi A, Gutierrez C, Lee E, Paramasivan CN, Abimiku A, Spector S, Roscigno G, Nkengasong J. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clin Microbiol Rev 2011;24:314-350.